11/15/2007 | SS | GPC Biotech to reduce headcount
|
1/24/2007 | PP | New Issue: GPC Biotech settles €33.64 million private placement of stock
|
11/9/2006 | BT | GPC Biotech reports 171% increase in revenues, burns €18.2 million during first nine months of 2006
|
9/27/2006 | BT | Altana sells its entire 7.1% stake in GPC Biotech
|
9/25/2006 | BT | Spectrum, GPC Biotech, Pharmion say satraplatin trial in prostate cancer yields positive results
|
9/25/2006 | BT | Market Commentary: Acorda skyrockets on trial data; GPC, Pharmion, Spectrum rise; Dendreon steady on rivals' news
|
8/2/2006 | BT | GPC tests satraplatin plus Tarceva in patients with advanced non-small cell lung cancer
|
7/12/2006 | BT | GPC Biotech submits non-clinical section of rolling NDA for prostate cancer drug satraplatin
|
6/8/2006 | BT | Pharmion, GPC Biotech, Spectrum: Monitoring board recommends satraplatin phase 3 trial continue
|
6/6/2006 | BT | GPC Biotech, Pharmion, Spectrum say new satraplatin clinical data shows cancer drug well-tolerated
|
5/17/2006 | BT | GPC Biotech, Pharmion recommended for analysis of satraplatin phase 3 trial
|
5/16/2006 | BT | Pharmion, GPC begin phase 1 trial of satraplatin with Xeloda in patients with advanced solid tumors
|
5/4/2006 | BT | Market Commentary: Bausch & Lomb stock sinks after buyback offering to avoid default; ImmunoGen stock up on earnings
|
4/25/2006 | BT | Independent board recommends GPC Biotech continue phase 3 trial of Satraplatin for prostate cancer
|
4/3/2006 | BT | GPC Biotech: Preclinical data shows satraplatin with docetaxel superior in treating lung cancer
|
3/15/2006 | BT | GPC Biotech 4Q net loss widens; company predicts doubling of revenue in 2006
|
2/27/2006 | BT | GPC, Pharmion announce new data that shows satraplatin effective in prostate cancer patients
|
2/24/2006 | BT | Market Commentary: Corautus, Cepheid deals emerge; BioMarin bounces; GCP gains on PIPEs deal; Par pounced on news
|
2/24/2006 | PP | Market Commentary: Remote Dynamics raises $5.75 million in note sale; Dalrada wraps $5 million PIPE
|
2/24/2006 | BTPP | New Issue: GPC Biotech raises €36.23 million in stock placement
|
2/14/2006 | BT | European regulators recommend orphan drug status for GPC Biotech's multiple myeloma drug
|
1/27/2006 | BT | GPC Biotech's 1D09C3 receives orphan drug status for chronic lymphocytic leukemia in Europe
|
1/23/2006 | BT | Spectrum, GPC Biotech license cancer drug satraplatin to Pharmion
|
12/20/2005 | BT | GPC Biotech signs pact for cancer drug with Pharmion
|
12/15/2005 | BT | Spectrum, GPC Biotech begin rolling NDA for cancer drug satraplatin
|
12/9/2005 | BT | Patient enrollment begins for GPC Biotech's phase 2 study of satraplatin with Taxol to treat lung cancer
|
12/5/2005 | BT | GPC Biotech reaches target enrollment in phase 3 trial of satraplatin for prostate cancer
|
11/16/2005 | BT | Spectrum, GPC Biotech say studies show satraplatin combination results in therapeutic synergy against cancer
|
11/9/2005 | BT | GPC Biotech gets OK to begin human testing of anti-cancer antibody 1D09C3
|
11/2/2005 | BT | GPC Biotech begins satraplatin phase-2 trial with metastatic breast cancer patients
|